ES2553332T3 - Métodos y composiciones para el tratamiento de enfermedades - Google Patents
Métodos y composiciones para el tratamiento de enfermedades Download PDFInfo
- Publication number
- ES2553332T3 ES2553332T3 ES07870731.2T ES07870731T ES2553332T3 ES 2553332 T3 ES2553332 T3 ES 2553332T3 ES 07870731 T ES07870731 T ES 07870731T ES 2553332 T3 ES2553332 T3 ES 2553332T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- polynucleotide
- promoter
- expression
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 94
- 201000010099 disease Diseases 0.000 title claims abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 76
- 238000011282 treatment Methods 0.000 title description 13
- 239000000203 mixture Substances 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 155
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 81
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 81
- 239000002157 polynucleotide Substances 0.000 claims abstract description 81
- 230000014509 gene expression Effects 0.000 claims abstract description 76
- 239000003550 marker Substances 0.000 claims abstract description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 61
- 229920001184 polypeptide Polymers 0.000 claims abstract description 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 60
- 231100000518 lethal Toxicity 0.000 claims abstract description 58
- 230000001665 lethal effect Effects 0.000 claims abstract description 58
- 230000000694 effects Effects 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 285
- 239000013598 vector Substances 0.000 claims description 54
- 210000000130 stem cell Anatomy 0.000 claims description 33
- 238000003780 insertion Methods 0.000 claims description 27
- 230000037431 insertion Effects 0.000 claims description 27
- 108010077544 Chromatin Proteins 0.000 claims description 12
- 210000003483 chromatin Anatomy 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 238000003153 stable transfection Methods 0.000 claims description 4
- 238000003146 transient transfection Methods 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 210000004216 mammary stem cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 32
- 230000001939 inductive effect Effects 0.000 description 30
- 108010091086 Recombinases Proteins 0.000 description 27
- 102000018120 Recombinases Human genes 0.000 description 27
- 230000010354 integration Effects 0.000 description 21
- 206010013023 diphtheria Diseases 0.000 description 20
- 108091023040 Transcription factor Proteins 0.000 description 19
- 102000040945 Transcription factor Human genes 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 16
- -1 for example Proteins 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 13
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 12
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108700020796 Oncogene Proteins 0.000 description 8
- 102000043276 Oncogene Human genes 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 239000004098 Tetracycline Substances 0.000 description 6
- 102000006601 Thymidine Kinase Human genes 0.000 description 6
- 108020004440 Thymidine kinase Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 102000000311 Cytosine Deaminase Human genes 0.000 description 5
- 108010080611 Cytosine Deaminase Proteins 0.000 description 5
- 102000016607 Diphtheria Toxin Human genes 0.000 description 5
- 108010053187 Diphtheria Toxin Proteins 0.000 description 5
- 235000011449 Rosa Nutrition 0.000 description 5
- 238000002679 ablation Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 210000004976 peripheral blood cell Anatomy 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100022002 CD59 glycoprotein Human genes 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 3
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 3
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 3
- 102000008763 Neurofilament Proteins Human genes 0.000 description 3
- 108010088373 Neurofilament Proteins Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000012966 insertion method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000629617 Homo sapiens Protein sprouty homolog 4 Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 2
- 108010057988 ecdysone receptor Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010008705 Mucin-2 Proteins 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 108010008699 Mucin-4 Proteins 0.000 description 1
- 102100022693 Mucin-4 Human genes 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100439689 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-4 gene Proteins 0.000 description 1
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 1
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 108010010574 Tn3 resolvase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0093—Purging against cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/724—Glycosyltransferases (EC 2.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82038106P | 2006-07-26 | 2006-07-26 | |
| US820381P | 2006-07-26 | ||
| US88909507P | 2007-02-09 | 2007-02-09 | |
| US889095P | 2007-02-09 | ||
| PCT/US2007/016747 WO2008073154A2 (en) | 2006-07-26 | 2007-07-26 | Methods and compositions for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2553332T3 true ES2553332T3 (es) | 2015-12-07 |
Family
ID=39512236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07870731.2T Active ES2553332T3 (es) | 2006-07-26 | 2007-07-26 | Métodos y composiciones para el tratamiento de enfermedades |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20100003226A1 (enExample) |
| EP (1) | EP2043662B1 (enExample) |
| JP (1) | JP2009544711A (enExample) |
| KR (1) | KR20090035011A (enExample) |
| AU (1) | AU2007332980A1 (enExample) |
| CA (1) | CA2658836C (enExample) |
| DK (1) | DK2043662T3 (enExample) |
| ES (1) | ES2553332T3 (enExample) |
| HU (1) | HUE027142T2 (enExample) |
| IL (1) | IL196638A (enExample) |
| MX (1) | MX2009000966A (enExample) |
| NZ (1) | NZ575075A (enExample) |
| PL (1) | PL2043662T3 (enExample) |
| PT (1) | PT2043662E (enExample) |
| RU (1) | RU2468820C2 (enExample) |
| WO (1) | WO2008073154A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013109944A1 (en) * | 2012-01-18 | 2013-07-25 | The Trustees Of The University Of Pennsylvania | Methods for assessing risk for cancer using biomarkers |
| KR102452803B1 (ko) | 2012-05-09 | 2022-10-07 | 캔텍스 파마슈티칼즈, 인크. | 골수억제의 치료 |
| WO2016133907A1 (en) * | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Adoptive cell transfer methods |
| EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| JP6976244B2 (ja) | 2015-11-11 | 2021-12-08 | プレシゲン，インコーポレイテッド | 心臓状態および他の病態の処置のための複数の生物学的に活性なポリペプチドを単一のベクターから発現させるための組成物および方法 |
| US20210128639A1 (en) * | 2017-05-09 | 2021-05-06 | Keio University | Cell preparation for treating brain tumor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| EP1188448A3 (en) * | 1994-03-15 | 2002-04-17 | Prizm Pharmaceuticals, Inc. | Heparin-binding growth factors for gene therapy and anterior eye disorders |
| WO1996036362A1 (en) * | 1995-05-16 | 1996-11-21 | Prizm Pharmaceuticals, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
| EP0923387B1 (en) * | 1996-06-24 | 2001-09-26 | Selective Genetics, Inc. | Heparin-coated medical devices for intravenous use containing heparin-binding growth factor conjugates |
| JP2002504340A (ja) * | 1998-02-19 | 2002-02-12 | セイント．ジュード チルドレンズ リサーチ ホスピタル | ヒト腫瘍細胞類を感作しおよびヒト腫瘍細胞の増殖を阻害するための組成物および方法 |
| US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| DE60043889D1 (en) * | 1999-06-07 | 2010-04-08 | Tet Systems Holding Gmbh & Co | Tet repressor basierte transkriptionale regulatorische proteine |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| EP1266015B1 (en) | 2000-03-22 | 2006-08-30 | RheoGene Holdings Inc. | Ecdysone receptor-based inducible gene expression system |
| DK1311661T3 (da) * | 2000-08-14 | 2012-11-26 | Us Gov Health & Human Serv | Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| AU2002248372B8 (en) * | 2001-01-19 | 2008-03-20 | Vegenics Limited | FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| JP4994563B2 (ja) | 2001-02-20 | 2012-08-08 | イントレキソン コーポレーション | 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用 |
| JP4955905B2 (ja) | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | キメラレチノイドｘ受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用 |
| WO2002066613A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene Holdings, Inc | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system |
| DK1373470T3 (da) | 2001-02-20 | 2013-07-29 | Intrexon Corp | Hidtil ukendte substitutionsmutantreceptorer og deres anvendelse i et cellekernereceptorbaseret inducerbart genekspressionssystem |
| US6828102B2 (en) * | 2001-11-20 | 2004-12-07 | Albany Medical College | Plasmids and methods for monitoring endonuclease digestion efficiency |
| EP1327688A1 (en) * | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| WO2004016791A1 (en) * | 2002-08-01 | 2004-02-26 | Evolva Ltd | Methods of mixing large numbers of heterologous genes |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| WO2004111074A2 (en) * | 2003-05-30 | 2004-12-23 | The Cleveland Clinic Foundation | In vivo production of a clostridial neurotoxin light chain peptide |
| CA2436196A1 (en) * | 2003-07-25 | 2005-01-25 | Oncolytics Biotech Inc. | Oncolytic virus for purging cellular compositions of cells of lymphoid malignancies |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090170727A1 (en) | 2004-05-18 | 2009-07-02 | Intrexon Corporation | Methods for dynamic vector assembly of dna cloning vector plasmids |
-
2007
- 2007-07-26 MX MX2009000966A patent/MX2009000966A/es active IP Right Grant
- 2007-07-26 ES ES07870731.2T patent/ES2553332T3/es active Active
- 2007-07-26 HU HUE07870731A patent/HUE027142T2/en unknown
- 2007-07-26 EP EP07870731.2A patent/EP2043662B1/en not_active Not-in-force
- 2007-07-26 PT PT78707312T patent/PT2043662E/pt unknown
- 2007-07-26 NZ NZ575075A patent/NZ575075A/en not_active IP Right Cessation
- 2007-07-26 PL PL07870731T patent/PL2043662T3/pl unknown
- 2007-07-26 KR KR1020097003901A patent/KR20090035011A/ko not_active Ceased
- 2007-07-26 JP JP2009521823A patent/JP2009544711A/ja active Pending
- 2007-07-26 WO PCT/US2007/016747 patent/WO2008073154A2/en not_active Ceased
- 2007-07-26 RU RU2009103208/15A patent/RU2468820C2/ru not_active IP Right Cessation
- 2007-07-26 AU AU2007332980A patent/AU2007332980A1/en not_active Abandoned
- 2007-07-26 CA CA2658836A patent/CA2658836C/en not_active Expired - Fee Related
- 2007-07-26 DK DK07870731.2T patent/DK2043662T3/en active
- 2007-07-26 US US12/374,691 patent/US20100003226A1/en not_active Abandoned
-
2009
- 2009-01-21 IL IL196638A patent/IL196638A/en active IP Right Grant
-
2014
- 2014-11-07 US US14/535,758 patent/US20150132265A1/en not_active Abandoned
-
2017
- 2017-01-27 US US15/417,598 patent/US20170191027A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1129596A1 (en) | 2009-12-04 |
| US20170191027A1 (en) | 2017-07-06 |
| MX2009000966A (es) | 2009-03-05 |
| IL196638A (en) | 2013-11-28 |
| EP2043662B1 (en) | 2015-09-09 |
| HUE027142T2 (en) | 2016-08-29 |
| IL196638A0 (en) | 2009-11-18 |
| CA2658836A1 (en) | 2008-06-19 |
| NZ575075A (en) | 2011-10-28 |
| RU2009103208A (ru) | 2010-09-10 |
| KR20090035011A (ko) | 2009-04-08 |
| US20100003226A1 (en) | 2010-01-07 |
| JP2009544711A (ja) | 2009-12-17 |
| DK2043662T3 (en) | 2015-12-14 |
| CA2658836C (en) | 2017-11-28 |
| EP2043662A4 (en) | 2010-04-14 |
| PT2043662E (pt) | 2015-11-25 |
| AU2007332980A1 (en) | 2008-06-19 |
| WO2008073154A3 (en) | 2008-12-04 |
| RU2468820C2 (ru) | 2012-12-10 |
| EP2043662A2 (en) | 2009-04-08 |
| PL2043662T3 (pl) | 2016-03-31 |
| WO2008073154A2 (en) | 2008-06-19 |
| US20150132265A1 (en) | 2015-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression | |
| Tamai et al. | Colonic hamartoma development by anomalous duplication in Cdx2 knockout mice | |
| Mrowka et al. | Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features | |
| US20170191027A1 (en) | Methods and Compositions For Treating Disease | |
| CN107532142A (zh) | 使用同源重组改造间充质干细胞 | |
| JP2005528115A (ja) | 幹細胞および癌幹細胞を同定および単離する方法 | |
| JP2019058176A (ja) | 新規方法 | |
| US20050130302A1 (en) | Method and composition for regulating expansion of stem cells | |
| Senf et al. | Chemokine signaling is required for homeostatic and injury-induced neurogenesis in the olfactory epithelium | |
| CN114245803A (zh) | 用于重构小神经胶质细胞的方法和组合物 | |
| JP2016127833A (ja) | 癌治療のための薬剤標的としてのＦｒａ−１標的遺伝子 | |
| CN112601812A (zh) | 基因疗法 | |
| Lam et al. | RETRACTED: Stem cells in prostate and prostate cancer development | |
| Lin et al. | Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation | |
| Varga et al. | Tissue-specific requirement for the GINS complex during zebrafish development | |
| Matsui et al. | Caspase 9-induced apoptosis enables efficient fetal cell ablation and disease modeling | |
| CN120603954A (zh) | 激活异染色质基因的方法及应用 | |
| HK1129596B (en) | Methods and compositions for treating disease | |
| CN101516383A (zh) | 治疗疾病的方法和组合物 | |
| JP2009502159A (ja) | ガン成長ならびにｄｎａ損傷に基づく疾患のマーカーとしてのスネイルの段階的発現 | |
| Varga et al. | The GINS complex is required for the survival of rapidly proliferating retinal and tectal progenitor cells during zebrafish development | |
| Boyer | DNMT3b's Role in Hematopoietic Stem Cells | |
| Onistschenko | Stem cell homeostasis in medaka neuromasts–Keratin 15 as a regulator of proliferation | |
| Casey | Zebrafish as a Tool to Understand Developmental Mechanisms in Pediatric Disease | |
| Murray | Suppression of neuroblastoma tumorigenesis using ENU mutagenesis in the Th-MYCN mouse model of neuroblastoma |